Right now, roughly 13% of Black Americans carry two high-risk variants of a gene called APOL1, and most of them have no idea their kidneys may be quietly heading toward failure. Standard blood and urine tests often look perfectly normal for years, right up until the damage becomes severe and, in many cases, irreversible. A study published in Nature Medicine in June 2026 offers the clearest path yet toward changing that timeline: a nine-protein blood test that can flag the risk of kidney failure up to a decade before symptoms surface.
The test is called the APOL1 Proteomic Risk Score, or APRS. It requires nothing more than a standard blood draw, and it was built using samples from people whose kidney function still looked completely normal at the time the blood was collected. For a disease that disproportionately devastates Black communities and often arrives without warning, the ability to see trouble coming years in advance could reshape how doctors approach prevention.
What the test measures and how it was built
The APRS works by measuring the levels of nine specific proteins circulating in the blood. Researchers at Penn Medicine developed the score using plasma samples from participants in the Penn Medicine BioBank who carried two copies of APOL1 high-risk gene variants but still had healthy kidney filtration rates, measured by a metric called estimated glomerular filtration rate (eGFR). The goal was to find molecular signals that precede kidney decline, not merely confirm damage already underway.
The statistical model behind the score accounts for age, sex, baseline kidney function, and albuminuria, which is a measure of protein leaking into the urine that signals early kidney stress. Together, the nine proteins outperformed these traditional clinical markers at predicting a composite outcome: either a 40% or greater drop in kidney filtration or outright kidney failure within 10 years.
Crucially, the researchers did not stop at testing the score in their own patient population. They validated it against two large, independent datasets: the Atherosclerosis Risk in Communities (ARIC) study, a decades-long cohort sponsored by the National Heart, Lung, and Blood Institute, and the UK Biobank, which tracks roughly half a million participants across Britain. Clearing validation in two separate populations on two continents is a high bar in biomarker science. It strongly suggests the APRS is picking up genuine biological risk rather than statistical patterns unique to one hospital system.
Participants with higher APRS scores were substantially more likely to experience serious kidney decline during follow-up, even after researchers accounted for baseline kidney function and urine protein levels. In the external ARIC and UK Biobank cohorts, the score held up, retaining meaningful predictive power across different populations and laboratory methods.
Why this matters for health equity
APOL1 high-risk variants are most common among people with recent West African ancestry. In the United States, that translates to a genetic risk factor concentrated in Black communities, contributing to a well-documented disparity: Black Americans are roughly three to four times more likely than white Americans to develop kidney failure, according to data from the United States Renal Data System. Not all of that gap is driven by APOL1, but the gene is a significant contributor, and until now, there has been no reliable way to identify which carriers are most likely to progress.
Standard kidney tests can remain reassuringly normal in APOL1 carriers for years before a rapid, steep decline. By the time conventional screening catches the problem, the window for early intervention has often closed. The APRS is designed to fill exactly that gap: identifying the highest-risk individuals while their kidneys still appear healthy, creating time for closer monitoring and, potentially, earlier treatment.
It is also worth noting that the baseline kidney measurements used in the APRS study reflect updated, race-neutral equations for estimating filtration rate. A landmark 2021 study in the New England Journal of Medicine provided the evidence for removing race as a variable from eGFR calculations, a change now adopted by major medical organizations. That shift means the APRS was built on a more equitable measurement foundation, reducing the chance that outdated race-based adjustments distorted the score’s accuracy.
How it compares to earlier proteomic work
The APRS is not the first attempt to use blood proteins to predict kidney outcomes. A 2023 study published in Nature Communications developed a 65-protein model from the Chronic Renal Insufficiency Cohort (CRIC) that predicted severe kidney decline within 10 years. That model was also validated in the ARIC cohort.
The key difference is the target population. The 65-protein panel was designed for patients who already had chronic kidney disease. The nine-protein APRS is aimed at people whose kidneys still look fine by every conventional measure but who carry a genetic predisposition to rapid decline. Catching risk before damage registers on standard labs is the central advance.
What still needs to happen before this reaches clinics
A validated research score is not the same as a test a doctor can order on Monday morning. Several significant gaps remain.
Cost and coverage are unknown. The published research does not specify what the APRS would cost per patient in a clinical laboratory, and no insurer has announced coverage. Proteomics technology has become cheaper over the past decade, but commercial pricing for a nine-protein clinical panel has not been established.
There is no proven treatment pathway tied to the score. Identifying risk is only half the equation. The drug inaxaplin, developed by Vertex Pharmaceuticals, showed reductions in proteinuria in a small, open-label phase 2a trial involving APOL1 carriers with a severe form of kidney scarring called focal segmental glomerulosclerosis. Those results, published in the New England Journal of Medicine, are promising but preliminary. No prospective trial has tested whether using the APRS to guide early treatment with inaxaplin or similar drugs can actually prevent kidney failure. Until that evidence exists, the test identifies risk without a matched intervention.
The 10-year prediction window is modeled, not yet observed in real time. The APRS performed well statistically in retrospective cohorts, but no study has yet enrolled patients based on their APRS result, intervened early, and tracked outcomes forward. That distinction matters for clinicians deciding how aggressively to act on a high score.
Performance across diverse real-world settings is untested. The derivation and validation cohorts, while large and geographically varied, may not fully capture patients with multiple chronic conditions, limited healthcare access, or environmental exposures that influence kidney health. Whether the same risk thresholds hold in community clinics, safety-net hospitals, or healthcare systems outside the U.S. and U.K. remains an open question.
Genetic testing infrastructure is a prerequisite. The APRS is designed for people who already know they carry two APOL1 risk variants. That means its usefulness depends on access to genetic screening and counseling, services that are unevenly distributed. Policies around when to offer APOL1 testing, how to communicate results, and how to guard against genetic discrimination are still evolving, and the APRS does not yet have a defined place within those frameworks.
What this means for patients and doctors right now
For people who know they carry two APOL1 risk variants, the APRS study reinforces something actionable today, even before the test itself becomes available: regular kidney monitoring matters. Blood pressure management, blood sugar control for those with diabetes, and ongoing conversations with a doctor about kidney health are the current best tools. The study does not change clinical guidelines, but it adds urgency to the case for staying vigilant.
For clinicians, the APRS represents a tool on the near horizon rather than one ready for immediate use. Its value right now is scientific: it sharpens the understanding of how molecular signals in the blood foreshadow kidney injury long before creatinine levels or urine tests raise alarms. If future intervention trials show that acting on an early APRS flag can slow or prevent kidney failure, the score could become a cornerstone of a broader strategy to reduce one of the starkest racial disparities in American medicine.
The peer-reviewed Nature Medicine report is the strongest piece of evidence here, documenting the full derivation, statistical methods, and multi-cohort validation. What it proves is that nine blood proteins, measured together, can stratify 10-year kidney risk among APOL1 carriers better than standard clinical tools. What it suggests, but cannot yet prove, is that knowing that risk a decade early could change outcomes. Closing that gap is the work that comes next, and it will determine whether this breakthrough in prediction becomes a breakthrough in prevention.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
